Fulvestrant (CAS 129453-61-8) is a selective oestrogen receptor degrader (SERD) and pure oestrogen receptor antagonist used in the treatment of hormone receptor–positive (HR+), HER2-negative advanced or metastatic breast cancer. It binds competitively to the oestrogen receptor, accelerates its degradation and eliminates receptor-mediated signalling, thereby inhibiting tumour growth in ER-dependent cancers.
Fulvestrant 129453-61-8 supplied by TCS GROUP is an injectable Active Pharmaceutical Ingredient (API) with high purity and regulatory-oriented documentation. Clinical studies, including the FALCON trial, have shown that fulvestrant can provide significant progression-free survival benefits compared with aromatase inhibitors in selected ER+ patient populations.
As an intramuscular depot formulation, fulvestrant imposes stringent requirements on sterility, particle size, solvent systems and excipient compatibility. TCS INDUSTRIES LIMITED supports partners with comprehensive technical data, impurity profiles and guidance on stability, helping manufacturers develop robust long-acting injections that maintain consistent drug exposure over the dosing interval.
Fulvestrant sits at the core of the TCS
Active Pharmaceutical Ingredient
portfolio for oncology, and is often positioned alongside other chemotherapeutic APIs such as:
- Epirubicin HCl 56390-09-1 – an anthracycline used in adjuvant and metastatic breast cancer regimens, sometimes in combination with endocrine therapies.
- Doxorubicin HCl 25316-40-9 – a foundational anthracycline chemotherapy agent in numerous solid tumour and haematologic protocols.
Sourcing multiple oncology APIs from TCS GROUP allows companies to streamline supplier qualification, harmonise quality systems and coordinate stability and regulatory strategies. Fulvestrant’s role as an injectable SERD also aligns with the emerging generation of oral SERDs, providing continuity between established parenteral therapy and next-generation endocrine agents.
With Fulvestrant 129453-61-8 from TCS INDUSTRIES LIMITED, manufacturers gain a trusted source of a clinically proven endocrine therapy API, backed by strong technical support and a comprehensive oncology portfolio.